Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes

Novo Nordisk announced new real-world trial data indicating its weight-loss drug Wegovy (semaglutide) reduced the risk of heart attack, stroke, or death by 57% more than Eli Lilly's tirzepatide in overweight or obese patients with cardiovascular disease. While the study was not a randomized controlled trial and involved low event numbers, Novo Nordisk asserts the cardiovascular benefits are specific to semaglutide, potentially offering a significant competitive advantage. This positive development, which saw Novo Nordisk shares rise approximately 3%, provides a boost for the Danish pharma giant as it navigates challenges in the key U.S. market, including declining market share, policy uncertainty, and competition from compounding pharmacies, though analysts note the market reaction was measured given the dynamic competitive landscape.

Analysis

Novo Nordisk's new real-world study data suggests its drug Wegovy provides a 57% greater reduction in cardiovascular event risk compared to Eli Lilly's tirzepatide, a potential differentiator that prompted a 3% rise in its share price. However, the significance of this finding is tempered by key caveats: the study was not a randomized controlled trial—the gold standard for clinical efficacy—and involved a very low number of adverse events (0.1% for Wegovy users). While Novo Nordisk frames this as evidence of a unique benefit specific to its semaglutide molecule, analysts remain cautious, noting the market is "not getting carried away." This positive news arrives amidst considerable headwinds for the Danish firm, including documented share price declines in 2024 and 2025, falling U.S. market share, competition from copycat compounding treatments, and persistent uncertainty around U.S. drug pricing policies. Furthermore, UBS analysts note that Wegovy's growth may be "plateauing," a sentiment echoed by Denmark's decision to halve its economic growth forecast, partly due to Novo's weaker outlook.

Key Decisions for Investors

• Investors should view the new cardiovascular data as a potential marketing advantage for Novo Nordisk, but must weigh this against the study's real-world (non-RCT) design and the low number of observed events.
• Monitor Novo Nordisk's U.S. sales figures and market share closely, as analysts flag potential growth plateauing due to strong competition from Eli Lilly's Zepbound and compounding pharmacies, which could offset the positive sentiment from this trial.
• The ongoing U.S. political climate, including potential drug pricing reforms and trade tariffs under the Section 232 investigation, remains a significant source of volatility and a key risk factor to consider in any investment thesis for Novo Nordisk.
• While this data favors Wegovy on cardiovascular protection, investors should continue to track developments in oral formulations from both Novo Nordisk and Eli Lilly, as this represents a major future catalyst for the sector.